Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06493760 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

StatusRecruiting
PhasePhase 2
Started2024-09-03
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2024-09-04
Not Yet Recruiting→Recruiting Study Identification, Study Status, Oversight, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-08→confirmed 2024-09-03
Study sitesdetails revised at 1 of 1 site
2024-08-07
Study Status, Study Design, Arms and Interventions v1
Start date2024-07→2024-08
Enrollment target120→130
Study arms6→7
2024-07-09
Original filing
This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.
Trial Details
NCT Number NCT06493760
Lead Sponsor Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Conditions Metastatic Colorectal Cancer
Enrollment 130 participants
Start Date 2024-09-03
Primary Completion 2025-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2024-09-19